3 Reasons to Buy Bristol Myers Squibb Stock

Bristol Myers Squibb faces a major patent cliff, with Eliquis and Opdivo contributing over $24.4B in sales and U.S. exclusivity expiring in 2028. The article argues the company can offset this with a 50-compound pipeline, 10 targeted new medicines by decade-end, and growth from products like Camzyos (+97% YoY to $314M), Breyanzi (+56% to $411M), and Reblozyl (+16% to $555M). Investors are also offered a 4.6% dividend yield, with the payout at just 40% of 2026 earnings estimates and the stock valued at 8.5x 2026 earnings.

Analysis

BMY is trading like a late-cycle ex-growth cash cow, but the market may be underpricing the convexity of pipeline optionality. The key second-order effect is that a successful new-asset ramp can matter more than the patent cliff itself: if the next 12-18 months deliver even one credible label expansion or phase-3 win, sentiment can re-rate before the revenue bridge is fully visible in fundamentals. That makes the stock less a near-term earnings story and more a catalyst-driven “prove-it” asset with asymmetric upside if execution is merely adequate.

The biggest winner in the ecosystem is likely JNJ, not because of direct revenue transfer, but because its partnership exposure gives it a levered claim on success without bearing full single-asset risk. Conversely, generic and biosimilar competitors are not the only threat to the legacy franchise; the more important pressure comes from capital allocation crowding, where any disappointment in launch cadence forces the company to defend the dividend and pipeline at the same time. That can compress flexibility for M&A or buybacks precisely when the market starts demanding evidence.

The consensus likely misses how much of the downside is already financed by the valuation and yield. At this multiple, the stock does not need robust growth to work; it only needs earnings to flatten less than feared through 2027, which is a lower bar than most investors assume. The real tail risk is binary: a negative readout on the Alzheimer’s psychosis program would remove the cleanest re-rating catalyst and could trap the stock in a high-yield value bucket for years.

Near term, this is a catalyst trading name more than a fundamental momentum long. The first real inflection should be around the upcoming phase-3 readout, with positioning likely to remain range-bound until data force a revision of long-dated estimates. If the readout is positive, the move should be disproportionately large because short interest and yield-seeking ownership create a thin air pocket above current levels; if negative, downside should be slower but more grinding as the market reprices terminal growth and capital return durability.

Key Decisions for Investors

• Long BMY into the next phase-3 catalyst with a 3-6 month horizon; thesis is limited downside from yield support and potentially large re-rating on any positive label-expansion signal.
• Buy BMY/JNJ pair: long BMY, short JNJ modestly sized for partnership exposure; use if you want to isolate optionality in BMY while hedging some broad large-cap pharma defensiveness.
• For event-driven accounts, buy BMY calls dated 6-9 months out rather than stock; implied upside is convex into the readout, while the dividend is not needed if the catalyst works.
• If the upcoming data disappoints, use any post-event gap lower to add only if the dividend remains covered and management reiterates 2026 guidance; otherwise avoid averaging down until the market stops treating it as a broken story.
• Short-dated hedge: pair a long BMY position with a small short basket of high-multiple biotech names for sector-neutral exposure to a rotation into cash-generative pharma.